Pfizer to Acquire Amplyx Pharmaceuticals

Through the acquisition, Pfizer will have access to Amplyx’s lead compound, Fosmanogepix (APX001), an investigational asset under development for the treatment of invasive fungal infections.

Pfizer announced on April 28, 2021 that it has acquired Amplyx Pharmaceuticals, a US-based pharmaceutical company focused on the development of therapies for diseases that affect people with compromised immune systems.

Through the acquisition, Pfizer will have access to Amplyx’s lead compound, Fosmanogepix (APX001), an investigational asset under development for the treatment of invasive fungal infections, Pfizer said in a company press release. The compound is currently involved in Phase II clinical trials to evaluate the safety and efficacy of intravenous and oral formulations for the treatment of patients with invasive fungal infections from molds, yeasts, and rare molds. Pfizer will also acquire Amplyx's early-stage pipeline that includes potential antiviral (MAU868) and antifungal (APX2039) therapies.

“The COVID-19 pandemic has been a stark reminder of the devastating impact of infectious diseases, highlighting the continuous need for new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral, and fungal infections,” said Angela Lukin, global president, Pfizer Hospital, in the press release. “We are deeply committed to helping patients suffering from infectious diseases, continuously seeking opportunities to build our portfolio of anti-infective therapies. We’ve already invested in assets that, if approved, could help address drug-resistant bacterial infections and critical viral infections; with this acquisition, we look forward to progressing the development of a novel anti-fungal as well.”

Source: Pfizer